Osmolarita slz u pacientů s těžkým syndromem suchého oka před a po aplikaci autologního séra.
Porovnání s hodnotami zdravých dobrovolníků

Česká verzia

Authors: G. Mahelková ^1,2; V. Veselá ³; P. Seidler Štangová ⁴; A. Židlická ¹; D. Dotřelová ¹; I. Fales ⁵; P. Skalická ⁴; K. Jirsová ³
Authors place of work: Oční klinika dětí a dospělých 2. LF UK a FN Motol, Praha, přednostka prof. MUDr. Dagmar Dotřelová, CSc., FEBO ¹; Ústav fyziologie 2. LF UK, Praha, vedoucí ústavu prof. RNDr. Václav Hampl, DrSc. ²; Laboratoř biologie a patologie oka, Ústav dědičných metabolických poruch VFN a 1. LF UK, Praha, vedoucí pracoviště prof. MUDr. Viktor Kožich, CSc. ³; Oční klinika 1. LF UK a VFN, Praha přednostka doc. MUD. Bohdana Kalvodová, CSc. ⁴; Oddělení buněčné terapie, Transfuziologický úsek, Ústav hematologie a krevní transfúze, Praha, přednostka doc. MUDr. Zdenka Gašová, CSc. ⁵
Published in the journal: Čes. a slov. Oftal., 71, 2015, No. 4, p. 184-188
Category: Original Article

Summary

Introduction:
Dry eye syndrome (DES) is a multifactorial disease of the tears and ocular surface. Recently, treatment with autologous serum eye drops (AS-ed) has been frequently used in these patients. Significant improvement correlates well with clinical, laboratory and subjective findings. It is assumed that one of the key factors in the development of the disease is increased tear osmolarity. The aims of our study were to test tear osmolarity measurements in clinical practice, to examine if osmolarity values differ before and after a 3-month application of 20% AS-ed, and to determine if the values differ between patients with severe DES and healthy individuals.

Methods:
The study included 35 patients with severe DES (Schirmer test <5 mm/5 min) and 23 healthy volunteers. Tear osmolarity values (TearLab Osmolarity System), the Schirmer test (ST1), vital ocular surface staining and subjective feelings (the OSDI questionnaire) were assessed in patients with DES before and after treatment with 20% AS-ed. Further, the tear osmolarity values were compared between healthy subjects and patients with DES before and after treatment with AS-ed.

Results:
The values of OSDI and vital staining significantly decreased in patients with DES after the treatment (p < 0.0001). ST1 and tear osmolarity did not change significantly after the treatment. ST1 values in healthy individuals were significantly higher (p < 0.0001) and the OSDI values significantly lower (p < 0.0001) than the results obtained in patients before and after treatment. Tear osmolarity was not statistically different between healthy subjects (306 mosmol/l) and patients with DES (302 and 301 mosmol/l before and after treatment respectively).

Conclusion:
We demonstrated a positive effect of AS treatment on the ocular surface in patients with DES. However, the osmolarity values did not differ before and after treatment with AS, and they also did not differ significantly between DES patients and healthy individuals. In accordance with other recent studies, our results raise questions concerning the value of the TearLab Osmolarity System for evaluating therapeutic effect and also as a tool for DES diagnosis.

Key words:
dry eye syndrome, autologous serum, osmolarity

Zdroje

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007; 5(2): 75–92.

2. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007; 5(2): 108–152.

3. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf, 2007; 5(2): 179–193.

4. Amparo, F., Jin, Y., Hamrah, P., Schaumberg, DA., et al: What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease? Am J Ophthalmol, 2014; 157(1): 69–77 e62.

5. Barabino, S., Chen, Y., Chauhan, S., et al: Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res, 2012; 31(3): 271–285.

6. Bunya, V. Y., Langelier, N., Chen, S., et al: Tear osmolarity in Sjogren syndrome. Cornea, 2013; 32(7): 922–927.

7. Celebi, A. R., Ulusoy, C., Mirza, GE.: The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol, 2014; 252(4): 619–626.

8. Farris, RL.: Tear osmolarity--a new gold standard? Adv Exp Med Biol, 1994; 350: 495–503.

9. Gilbard, JP., Farris, RL.: Tear osmolarity and ocular surface disease in keratoconjunctivitis sicca. Arch Ophthalmol, 1979; 97(9): 1642–1646.

10. Gilbard, JP., Farris, RL., Santamaria, J.: Osmolarity of tear microvolumes in keratoconjunctivitis sicca. Arch Ophthalmol, 1978; 96(4): 677–681.

11. Jacobi, C., Jacobi, A., Kruse, FE., et al.: Tear film osmolarity measurements in dry eye disease using electrical impedance technology. Cornea, 2011; 30(12): 1289–1292.

12. Jirsova, K., Brejchova, K., Krabcova, I., et al.: The application of autologous serum eye drops in severe dry eye patients; subjective and objective parameters before and after treatment. Curr Eye Res, 2013; 39(1): 21–30.

13. Jirsova, K., Hrdlickova, E., Alfakih, A., et al.: [The application of the autologous serum eye drops results in significant improvement of the conjunctival status in patients with the dry eye syndrome]. Čes a Slov Oftalmol, 2008; 64(2): 52–56.

14. Khanal, S., Millar, TJ.: Barriers to clinical uptake of tear osmolarity measurements. Br J Ophthalmol, 2012; 96(3): 341–344.

15. Kojima, T., Higuchi, A., Goto, E., et al.: Autologous serum eye drops for the treatment of dry eye diseases. Cornea, 2008; 27 Suppl 1: S25–30.

16. Kojima, T., Ishida, R., Dogru, M., et al.: The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol, 2005; 139(2): 242–246.

17. Lemp, MA.: Advances in understanding and managing dry eye disease. Am J Ophthalmol, 2008; 146(3): 350–356.

18. Lemp, MA., Bron, A. J., Baudouin, C., et al.: Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol, 2011; 151(5): 792–798 e791.

19. Lemp, MA., Foulks, GN., Pepose, JS.: Evaluation of tear osmolarity in non-Sjogren and Sjogren Syndrome dry eye patients with the TearLab system. Cornea, 2013; 32(3): 379-381.

20. Li, M., Du, C., Zhu, D., et al.: Daytime variations of tear osmolarity and tear meniscus volume. Eye Contact Lens, 2013; 38(5): 282–287.

21. Liu, H., Begley, C., Chen, M., et al.: A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci 2009; 50(8): 3671–3679.

22. McGinnigle, S., Naroo, SA., Eperjesi, F.: Evaluation of dry eye. Surv Ophthalmol, 2012; 57(4): 293–316.

23. Ogawa, Y., Okamoto, S., Mori, T., Yamada, M., Mashima, Y., Watanabe, R., Kuwana, M., Tsubota, K., Ikeda, Y., et al.: Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant, 2003; 31(7): 579–583.

24. Pepose, J. S., Sullivan, BD., Foulks, GN, et al.: The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials. Am J Ophthalmol, 2014; 157(1): 4–6 e1.

25. Perry, HD.: Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care, 2008; 14(3 Suppl): S79–87.

26. Quinto, GG., Campos, M., Behrens, A.: Autologous serum for ocular surface diseases. Arq Bras Oftalmol, 2008; 71(6 Suppl): 47–54.

27. Schiffman, RM., Christianson, MD., Jacobsen, G., et al.: Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol, 2000; 118(5): 615–621.

28. Sullivan, B.: Challenges in using signs and symptoms to evaluate new biomarkers of dry eye disease. Ocul Surf, 2014; 12(1): 2–9.

29. Sullivan, BD., Crews, L. A., Messmer, E. M., Foulks, G. N., Nichols, K. K., Baenninger, P., Geerling, G., Figueiredo, F., et al.: Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol, 2014; 92(2): 161–166.

30. Sullivan, BD., Crews, LA., Sonmez, B., et al.: Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea, 2012; 31(9): 1000–1008.

31. Sullivan, BD., Whitmer, D., Nichols, KK., et al.: An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci, 2010; 51(12): 6125–6130.

32. Suzuki, M., Massingale, ML., Ye, F., et al.: Tear osmolarity as a biomarker for dry eye disease severity. Invest Ophthalmol Vis Sci, 2010; 51(9): 4557–4561.

33. Szalai, E., Berta, A., Szekanecz, Z., et al.: Evaluation of tear osmolarity in non-Sjogren and Sjogren syndrome dry eye patients with the TearLab system. Cornea, 2012; 31(8): 867–871.

34. Tananuvat, N., Daniell, M., Sullivan, LJ., et al.: Controlled study of the use of autologous serum in dry eye patients. Cornea, 2001; 20(8): 802–806.

35. Tomlinson, A., Khanal, S., Ramaesh, K., et al.: Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci, 2006; 47(10): 4309–4315.

36. Urzua, CA., Vasquez, DH., Huidobro, A., et al.: Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res, 2012; 37(8): 684–688.

37. Versura, P., Profazio, V., Campos, EC.: Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res, 2010; 35(7): 553–564.

38. Yoon, D., Gadaria-Rathod, N., Oh, C., et al.: Precision and accuracy of TearLab osmometer in measuring osmolarity of salt solutions. Curr Eye Res, 2014; 39(12): 1247–1250.